FIALA, Ondrej, Pavel OSTASOV, Ondrej SOREJS, Vaclav LISKA, Tomáš BÜCHLER, Alexandr POPRACH a Jindrich FINEK. Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients. Cancers. BASEL: MDPI, roč. 11, č. 12, s. 1-13. ISSN 2072-6694. doi:10.3390/cancers11121856. 2019.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients
Autoři FIALA, Ondrej (203 Česká republika, garant), Pavel OSTASOV (203 Česká republika), Ondrej SOREJS (203 Česká republika), Vaclav LISKA (203 Česká republika), Tomáš BÜCHLER (203 Česká republika), Alexandr POPRACH (203 Česká republika, domácí) a Jindrich FINEK (203 Česká republika).
Vydání Cancers, BASEL, MDPI, 2019, 2072-6694.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30204 Oncology
Stát vydavatele Švýcarsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 6.126
Kód RIV RIV/00216224:14110/19:00112964
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.3390/cancers11121856
UT WoS 000507382100035
Klíčová slova anglicky colorectal cancer; bevacizumab; beta-blocker; outcome; hypertension
Štítky 14110811, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 17. 2. 2020 14:37.
Anotace
Background: Beta-adrenergic signalling plays an important role in several cancer-related processes, including angiogenesis. The impact of beta-blocker use on prognosis of cancer patients treated with antiangiogenic agents is unclear. The aim of this study was to evaluate the association between the incidental use of beta-blockers and the outcomes of patients with metastatic colorectal cancer (mCRC) treated with bevacizumab-based therapy. Methods: Clinical data from 514 mCRC patients treated with bevacizumab between 2005 and 2019 were analysed retrospectively. The association of progression-free survival (PFS) and overall survival (OS) with the incidental use of beta-blockers and other common antihypertensive drugs was assessed. Results: The median PFS and OS for patients using beta-blockers was 11.40 (95% confidence interval (CI) 10.10-13.61) months and 26.8 (95% CI 22.2-32.2) months compared with 8.30 (95% CI 7.80-9.57) and 21.0 (95% CI 17.8-23.8) months for patients not using beta-blockers (p = 0.006 and p = 0.009, respectively). In the Cox multivariate analysis, the use of beta-blockers was a significant factor predicting both PFS (hazard ratio (HR) = 0.763 (95% CI 0.606-0.960), p = 0.021) and OS (HR = 0.730 (95% CI 0.560-0.951), p = 0.020). Conclusions: The results of the present retrospective study suggest that there is a significant association between the use of beta-blockers and favourable outcomes of mCRC patients treated with bevacizumab-based therapy.
VytisknoutZobrazeno: 29. 3. 2024 02:28